Many/JJ advances/NNS in/IN research/NN regarding/VBG immuno/NN -/HYPH interactions/NNS with/IN cancer/NN were/VBD developed/VBN with/IN the/DT help/NN of/IN ordinary/JJ differential/JJ equation/NN (/-LRB- ODE/NN )/-RRB- models/NNS ./.
These/DT models/NNS ,/, however/RB ,/, are/VBP not/RB effectively/RB capable/JJ of/IN representing/VBG problems/NNS involving/VBG individual/JJ localisation/NN ,/, memory/NN and/CC emerging/VBG properties/NNS ,/, which/WDT are/VBP common/JJ characteristics/NNS of/IN cells/NNS and/CC molecules/NNS of/IN the/DT immune/JJ system/NN ./.
Agent/NNP -/HYPH based/VBN modelling/NN and/CC simulation/NN is/VBZ an/DT alternative/JJ paradigm/NN to/IN ODE/NN models/NNS that/WDT overcomes/VBZ these/DT limitations/NNS ./.
In/IN this/DT paper/NN we/PRP investigate/VBP the/DT potential/JJ contribution/NN of/IN agent/NN -/HYPH based/VBN modelling/NN and/CC simulation/NN when/WRB compared/VBN to/IN ODE/NN modelling/NN and/CC simulation/NN ./.
We/PRP seek/VBP answers/NNS to/IN the/DT following/VBG questions/NNS :/: Is/VBZ it/PRP possible/JJ to/TO obtain/VB an/DT equivalent/JJ agent/NN -/HYPH based/VBN model/NN from/IN the/DT ODE/NN formulation/NN ?/.
Do/VB the/DT outcomes/NNS differ/VBP ?/.
Are/VBP there/EX any/DT benefits/NNS of/IN using/VBG one/CD method/NN compared/VBN to/IN the/DT other/JJ ?/.
To/TO answer/VB these/DT questions/NNS ,/, we/PRP have/VBP considered/VBN three/CD case/NN studies/NNS using/VBG established/VBN mathematical/JJ models/NNS of/IN immune/JJ interactions/NNS with/IN early/JJ -/HYPH stage/NN cancer/NN ./.
These/DT case/NN studies/NNS were/VBD re-conceptualised/VBN under/IN an/DT agent/NN -/HYPH based/VBN perspective/NN and/CC the/DT simulation/NN results/NNS were/VBD then/RB compared/VBN with/IN those/DT from/IN the/DT ODE/NN models/NNS ./.
Our/PRP$ results/NNS show/VBP that/IN it/PRP is/VBZ possible/JJ to/TO obtain/VB equivalent/JJ agent/NN -/HYPH based/VBN models/NNS (/-LRB- i.e./FW implementing/VBG the/DT same/JJ mechanisms/NNS )/-RRB- ;/: the/DT simulation/NN output/NN of/IN both/DT types/NNS of/IN models/NNS however/RB might/MD differ/VB depending/VBG on/IN the/DT attributes/NNS of/IN the/DT system/NN to/TO be/VB modelled/VBN ./.
In/IN some/DT cases/NNS ,/, additional/JJ insight/NN from/IN using/VBG agent/NN -/HYPH based/VBN modelling/NN was/VBD obtained/VBN ./.
Overall/RB ,/, we/PRP can/MD confirm/VB that/IN agent/NN -/HYPH based/VBN modelling/NN is/VBZ a/DT useful/JJ addition/NN to/IN the/DT tool/NN set/NN of/IN immunologists/NNS ,/, as/IN it/PRP has/VBZ extra/JJ features/NNS that/WDT allow/VBP for/IN simulations/NNS with/IN characteristics/NNS that/WDT are/VBP closer/RBR to/IN the/DT biological/JJ phenomena/NN ./.
